The AstraZeneca PLC ADR AZN rose 1.25% to $68.81 Friday, on what proved to be an all-around positive trading session for the ...

AstraZeneca PLC closed 22.84% below its 52-week high of £133.88, which the company achieved on September 3rd.

Las acciones de las empresas farmacéuticas cayeron en todo el mundo después de que el presidente de EE.UU., Donald Trump, ...

AstraZeneca Plc lost its crown as the UK’s most valuable listed company after US President Donald Trump’s plans to lower drug ...

The market seemed underwhelmed by last week's earnings announcement from AstraZeneca PLC (LON:AZN) despite the healthy numbers. We did some analysis to find out why and believe that investors ...

Mereo BioPharma Group plc’s MREO share price has dipped by 5.63%, which has investors questioning if this is right time to ...

Best Pharma Stocks to Invest in Now. In this article, we are going to take a look at where AstraZeneca PLC (NASDAQ:AZN) ...

The market seemed underwhelmed by last week's earnings announcement from AstraZeneca PLC (LON:AZN) despite the healthy numbers. We did some analysis to find out why and believe that investors might be ...

Welcome ladies and gentlemen to AstraZeneca's Q1 2025 Results Conference Call for Investors and Analysts. Before I hand over to AstraZeneca, I'd like to read the Safe Harbor Statement. The company ...

Pathos AI Inc., a startup using artificial intelligence to develop new oncology drugs, today announced that it has raised ...

AstraZeneca PLC is set to release its Q1 2025 earnings on April 29, 2025.The consensus estimate for Q1 2025 revenue is $133.16 billion, and the earnings are expected to come in at $15.74 per share.

AstraZeneca PLC (LSE/STO/Nasdaq:LON:AZN) has announced positive results from the POTOMAC Phase III trial, which evaluated Imfinzi (durvalumab) in combination with Bacillus Calmette-Guérin (BCG ...